Form 8-K Editas Medicine, Inc. For: Nov 04
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Needham Starts NeoVolta (NEOV) at Buy
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Chardan Capital Markets Reiterates Buy Rating on Editas Medicine (EDIT)
November 5, 2024 4:19 PM ESTChardan Capital Markets analyst Geulah Livshits reiterated a Buy rating and $12.00 price target on Editas Medicine (NASDAQ: EDIT).
The analyst comments "EDIT (Buy, PT $12): 3Q24 Results; Reni-cel Data at ASH; In Vivo Updates in 1Q25. On 4 November, Editas Medicine reported 3Q24 results and... More
Editas Medicine (EDIT) PT Lowered to $5 at Barclays
November 5, 2024 5:23 AM ESTBarclays analyst Gena Wang lowered the price target on Editas Medicine (NASDAQ: EDIT) to $5.00 (from $7.00) while maintaining a Equalweight rating.
The analyst comments "Key takeaways. 3Q24 PR was incremental following recent strategic update (see EDIT - Strategic update mixed, 10/22/2024). Reni-cel (EDIT-301): Mgmt. reiterated... More
Editas Medicine (EDIT) PT Lowered to $8 at Truist Securities
November 4, 2024 12:25 PM ESTTruist Securities analyst Joon Lee lowered the price target on Editas Medicine (NASDAQ: EDIT) to $8.00 (from $12.00) while maintaining a Buy rating.
The analyst comments "3Q24: No surprises on the quarter post recent announcements (our prior takes - HERE and HERE). EDIT... More
